These studies have identified molecular heterogeneity within prostate cancer bone metastases, with two predominant subgroups, one subtype expressing higher levels of targets of the androgen receptor (AR) as well as Golgi-resident and mitochondrial proteins, the other sub-group expressing high levels of proteins involved in DNA-repair and cell proliferation [116]. This evidence concerns the gene AR and Familial prostate cancer.